Scarica l'app Stockscreener
30.02
8.34%
-2.73
Dopo l'orario di chiusura:
29.97
-0.05
-0.17%
Precedente Chiudi:
$32.75
Aprire:
$33.34
Volume 24 ore:
2.10M
Relative Volume:
1.98
Capitalizzazione di mercato:
$1.79B
Reddito:
$66.05M
Utile/perdita netta:
$-422.60M
Rapporto P/E:
-4.1401
EPS:
-7.251
Flusso di cassa netto:
$-384.73M
1 W Prestazione:
-17.44%
1M Prestazione:
-19.11%
6M Prestazione:
+9.40%
1 anno Prestazione:
-19.34%
Intervallo 1D:
$29.94
$33.34
Intervallo di 1 settimana:
$29.15
$38.74
Portata 52W:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Nome
Agios Pharmaceuticals Inc
Settore
Industria
Telefono
617-649-8600
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
30.02 | 2.20B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-20 | Reiterato | H.C. Wainwright | Buy |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-20 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-27 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Iniziato | Piper Sandler | Overweight |
| 2022-11-17 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-02-15 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Iniziato | Leerink Partners | Mkt Perform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-04-11 | Reiterato | Credit Suisse | Outperform |
| 2018-02-15 | Reiterato | Needham | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-08-10 | Reiterato | Needham | Buy |
| 2017-08-08 | Reiterato | SunTrust | Buy |
| 2017-08-02 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Downgrade | Janney | Buy → Neutral |
| 2017-01-17 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Iniziato | Needham | Buy |
| 2016-06-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Reiterato | SunTrust | Buy |
Mostra tutto
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
AGIO|Agios Pharmaceuticals Inc|Price:36.308|Chg%:-0.662 - TradingKey
Understanding the Setup: (AGIO) and Scalable Risk - Stock Traders Daily
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Agios Pharmaceuticals Inc (AGIO) Cash Flow - TradingKey
Agios Pharmaceuticals Inc (AGIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Agios Pharmaceuticals Inc (AGIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Agios Pharmaceuticals Inc (AGIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Agios Pharmaceuticals Inc (AGIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Agios Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AGIO - TradingView
Agios Pharmaceuticals Inc. (AGIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Agios Pharmaceuticals Inc (AGIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Imunon (IMNN) - The Globe and Mail
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development - Sahm
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program - Yahoo Finance
H.C. Wainwright lowers Agios Pharma price target to $52 on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright lowers Agios Pharma price target to $52 on trial data - Investing.com
Agios Pharmaceuticals (AGIO) Sees 13% Drop Following Trial Resul - GuruFocus
Agios Pharmaceuticals Reports Phase 2 Trial Results for Tebapiva - GuruFocus
Agios Pharmaceuticals (AGIO) Ends Development of Sickle Cell Dru - GuruFocus
AGIO Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Agios scraps sickle cell treatment after trial shows limited benefit - Reuters
Agios Pharmaceuticals stock falls on trial update - Investing.com
Agios Pharma Drops Sickle Cell Disease Drug After Phase 2 Data Disappoint - MedCity News
Agios pares loss after abandoning sickle cell asset tebapivat (AGIO:NASDAQ) - Seeking Alpha
Agios scraps sickle cell drug - BioPharma Dive
Why Agios Pharma, A Novo Rival, Just Pulled A Bearish Move - Investor's Business Daily
Trial miss for Agios Pharma’s tebapivat in sickle cell disease - The Pharma Letter
Agios scraps sickle cell drug programme on underwhelming Phase II data - Yahoo Finance
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset - BioSpace
Agios Shelves Tebapivat In Sickle Cell, Weeks After MDS Exit - insights.citeline.com
Why Is AGIO Stock Falling Today? - TradingView
Agios shares tumble after discontinuing sickle cell disease programme following Phase 2 trial (AGIO) - Yahoo Finance
Agios halts tebapivat development in sickle cell disease - Investing.com
Agios halts tebapivat development in sickle cell disease By Investing.com - Investing.com Nigeria
Agios Pharmaceuticals stock falls on trial update By Investing.com - Investing.com Canada
Agios Pharmaceuticals Reports Phase 2 Tebapivat Sickle Cell Disease Results, Discontinues Development of the Candidate - Quiver Quantitative
Agios Pharmaceuticals Shares Down 12.6% Prema - Moomoo
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease - The Manila Times
Tebapivat 5 mg Arm: 47.1% Hemoglobin Response; Agios Won’t Advance - Stock Titan
The Bull Case For Agios Pharmaceuticals (AGIO) Could Change Following FDA Priority Review For Mitapivat In Sickle Cell - simplywall.st
Agios gains FDA priority review for Pyrukynd label expansion - MSN
The Technical Signals Behind (AGIO) That Institutions Follow - Stock Traders Daily
Agios Pharmaceuticals (AGIO) Wins Priority Review, Is The Stock Now Fully Valued? - Sahm
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia - AOL.com
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $54 - Moomoo
AGIO 260717 45.00P (AGIO260717P45000) Latest Announcements - Moomoo
Agios Pharmaceuticals (NASDAQ: AGIO) director reports 1,447-share equity award and 2,894 RSUs - Stock Titan
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week - AOL.com
Is Agios Pharmaceuticals (AGIO) A Bargain After FDA Priority Review For Mitapivat? - Yahoo Finance
Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Agios Pharmaceuticals Inc Azioni (AGIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer |
Jul 01 '26 |
Sale |
37.56 |
4,007 |
150,503 |
84,645 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):